Computational analysis of cas proteins unlocks new potential in HIV-1 targeted gene therapy

IF 4.9 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
W. Dampier, Rachel Berman, M. Nonnemacher, B. Wigdahl
{"title":"Computational analysis of cas proteins unlocks new potential in HIV-1 targeted gene therapy","authors":"W. Dampier, Rachel Berman, M. Nonnemacher, B. Wigdahl","doi":"10.3389/fgeed.2023.1248982","DOIUrl":null,"url":null,"abstract":"Introduction: The human immunodeficiency virus type 1 (HIV-1) pandemic has been slowed with the advent of anti-retroviral therapy (ART). However, ART is not a cure and as such has pushed the disease into a chronic infection. One potential cure strategy that has shown promise is the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas gene editing system. It has recently been shown to successfully edit and/or excise the integrated provirus from infected cells and inhibit HIV-1 in vitro, ex vivo, and in vivo. These studies have primarily been conducted with SpCas9 or SaCas9. However, additional Cas proteins are discovered regularly and modifications to these known proteins are being engineered. The alternative Cas molecules have different requirements for protospacer adjacent motifs (PAMs) which impact the possible targetable regions of HIV-1. Other modifications to the Cas protein or gRNA handle impact the tolerance for mismatches between gRNA and the target. While reducing off-target risk, this impacts the ability to fully account for HIV-1 genetic variability.Methods: This manuscript strives to examine these parameter choices using a computational approach for surveying the suitability of a Cas editor for HIV-1 gene editing. The Nominate, Diversify, Narrow, Filter (NDNF) pipeline measures the safety, broadness, and effectiveness of a pool of potential gRNAs for any PAM. This technique was used to evaluate 46 different potential Cas editors for their HIV therapeutic potential.Results: Our examination revealed that broader PAMs that improve the targeting potential of editors like SaCas9 and LbCas12a have larger pools of useful gRNAs, while broader PAMs reduced the pool of useful SpCas9 gRNAs yet increased the breadth of targetable locations. Investigation of the mismatch tolerance of Cas editors indicates a 2-missmatch tolerance is an ideal balance between on-target sensitivity and off-target specificity. Of all of the Cas editors examined, SpCas-NG and SPRY-Cas9 had the highest number of overall safe, broad, and effective gRNAs against HIV.Discussion: Currently, larger proteins and wider PAMs lead to better targeting capacity. This implies that research should either be targeted towards delivering longer payloads or towards increasing the breadth of currently available small Cas editors. With the discovery and adoption of additional Cas editors, it is important for researchers in the HIV-1 gene editing field to explore the wider world of Cas editors.","PeriodicalId":73086,"journal":{"name":"Frontiers in genome editing","volume":"60 3","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in genome editing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fgeed.2023.1248982","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The human immunodeficiency virus type 1 (HIV-1) pandemic has been slowed with the advent of anti-retroviral therapy (ART). However, ART is not a cure and as such has pushed the disease into a chronic infection. One potential cure strategy that has shown promise is the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas gene editing system. It has recently been shown to successfully edit and/or excise the integrated provirus from infected cells and inhibit HIV-1 in vitro, ex vivo, and in vivo. These studies have primarily been conducted with SpCas9 or SaCas9. However, additional Cas proteins are discovered regularly and modifications to these known proteins are being engineered. The alternative Cas molecules have different requirements for protospacer adjacent motifs (PAMs) which impact the possible targetable regions of HIV-1. Other modifications to the Cas protein or gRNA handle impact the tolerance for mismatches between gRNA and the target. While reducing off-target risk, this impacts the ability to fully account for HIV-1 genetic variability.Methods: This manuscript strives to examine these parameter choices using a computational approach for surveying the suitability of a Cas editor for HIV-1 gene editing. The Nominate, Diversify, Narrow, Filter (NDNF) pipeline measures the safety, broadness, and effectiveness of a pool of potential gRNAs for any PAM. This technique was used to evaluate 46 different potential Cas editors for their HIV therapeutic potential.Results: Our examination revealed that broader PAMs that improve the targeting potential of editors like SaCas9 and LbCas12a have larger pools of useful gRNAs, while broader PAMs reduced the pool of useful SpCas9 gRNAs yet increased the breadth of targetable locations. Investigation of the mismatch tolerance of Cas editors indicates a 2-missmatch tolerance is an ideal balance between on-target sensitivity and off-target specificity. Of all of the Cas editors examined, SpCas-NG and SPRY-Cas9 had the highest number of overall safe, broad, and effective gRNAs against HIV.Discussion: Currently, larger proteins and wider PAMs lead to better targeting capacity. This implies that research should either be targeted towards delivering longer payloads or towards increasing the breadth of currently available small Cas editors. With the discovery and adoption of additional Cas editors, it is important for researchers in the HIV-1 gene editing field to explore the wider world of Cas editors.
对 Cas 蛋白的计算分析为 HIV-1 靶向基因疗法释放出新潜力
导言:随着抗逆转录病毒疗法(ART)的出现,人类免疫缺陷病毒 1 型(HIV-1)的流行速度有所减缓。然而,抗逆转录病毒疗法并不能治愈疾病,反而会使疾病发展成慢性感染。一种有希望治愈艾滋病的潜在策略是CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats)/Cas基因编辑系统。最近的研究表明,该系统可以成功地编辑和/或切除感染细胞中的整合前病毒,并在体外、体内和体外抑制 HIV-1。这些研究主要是利用 SpCas9 或 SaCas9 进行的。然而,人们也经常发现其他的 Cas 蛋白,并对这些已知蛋白进行改造。替代的 Cas 分子对临近的原间隔基序(PAM)有不同的要求,这影响了 HIV-1 的可能靶区。对 Cas 蛋白或 gRNA 处理的其他修改会影响对 gRNA 与靶之间错配的容忍度。在降低脱靶风险的同时,这也影响了全面考虑 HIV-1 基因变异性的能力:本稿件试图利用一种计算方法来研究这些参数选择,以调查 Cas 编辑器是否适合用于 HIV-1 基因编辑。提名、多样化、缩小、筛选(NDNF)管道可衡量任何 PAM 潜在 gRNA 库的安全性、广泛性和有效性。这项技术用于评估 46 种不同的潜在 Cas 编辑器的艾滋病治疗潜力:我们的研究发现,更宽泛的 PAM 能够提高 SaCas9 和 LbCas12a 等编辑器的靶向潜力,具有更大的有用 gRNAs 库,而更宽泛的 PAM 则减少了 SpCas9 有用 gRNAs 库,但增加了可靶向位置的广度。对 Cas 编辑器错配耐受性的研究表明,2 个错配耐受性是靶上灵敏度和脱靶特异性之间的理想平衡。在所有被研究的 Cas 编辑器中,SpCas-NG 和 SPRY-Cas9 对 HIV 的总体安全、广泛和有效的 gRNA 数量最多:讨论:目前,较大的蛋白质和较宽的 PAM 可提高靶向能力。讨论:目前,更大的蛋白质和更宽的 PAMs 能带来更好的靶向能力,这意味着研究应着眼于提供更长的有效载荷,或增加目前可用的小型 Cas 编辑器的广度。随着更多 Cas 编辑器的发现和采用,HIV-1 基因编辑领域的研究人员必须探索更广阔的 Cas 编辑器世界。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
0.00%
发文量
0
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信